Bridgebio Entered into an Exclusive License Agreement with BMS to Develop and Commercialize BBP-398 for the Treatment of Cancer

Shots:

BridgeBio to receive $90M up front, ~$815M in development, regulatory & sales milestones along with royalties. BMS will be responsible to fund the other development & commercial activities
BridgeBio obtains an option to acquire higher royalties in the US along with funding for a portion of development costs upon the initiation of registrational studies & continues to lead the P-I trial of BBP-398 as monothx. & in combination with additional support from BMS
In the 2021 agreement, BridgeBio & BMS collaborated to evaluate BBP-398 + Opdivo for advanced solid tumors with KRAS mutations. BridgeBio expands its P-I trial for solid tumors driven by mutations in the MAPK signaling pathway

Ref: Bridgebio | Image: Bridgebio 

Category: News